Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib PK, SNPs, and Adverse Effects in Chinese Renal Cell Carcinoma
ChiCTR-OPC-16008840Phase 4Recruiting
- Sponsor
- Department of Clinical Pharmacology, Affiliated Hospital of Military Medical Science
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sunitinib in renal cell carcinoma (RCC), sponsored by Department of Clinical Pharmacology, Affiliated Hospital of Military Medical Science. Primary endpoints: Plasma drug concentration, Single nucleotide polymorphisms and 1 more. Started Jul 2016; status: recruiting.
02
Drugs
sunitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on ChiCTR-OPC-16008840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-16008840.